Quality control of ALPHANATE through to point-of-use

Grifols provides the capability to trace the plasma used in the manufacturing process for ALPHANATE from the donor center to the final product.

ALPHANATE Quality Control Steps


Each vial of ALPHANATE is laser etched so its origins can always be traced

  • A call to Grifols with the laser-etched lot number can verify authenticity*
  • Holographic safety seal on each package to further deter tampering


ALPHANATE Hemophilia A & VWD Treatment

*Laser-etched identifier number on the vial may at times be covered by the label.


With PediGri®, track the quality and safety of the plasma units used in the manufacturing of ALPHANATE

PediGri is a system that provides easy and immediate access to additional information about the quality and safety of Grifols plasma-derived medicines:


Access to information related to each plasma donation:

  • Donation number
  • Virus screenings at the origin

Certificate of analysis, including:

  • Plasma origin
  • Virus screenings
  • Biochemical characteristics of the finished product

View a demo of the PediGri system

PediGri is a free service and provides healthcare professionals with transparent information about Grifols plasma-derived products.

Register for PediGri

ALPHANATE - Indications


ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A.
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery.


Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.